問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Radiation Therapy

Digestive System Department

Kaohsiung Municipal FENG-SHAN Hospital (在職)

Digestive System Department

更新時間：2023-09-19

郭垣宏
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

13Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭垣宏

List

41Cases

2019-11-30 - 2026-09-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2022-07-06 - 2026-12-31

Others

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2023-01-30 - 2028-11-27

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2023-02-01 - 2028-01-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Not yet recruiting6Sites

Recruiting4Sites

2026-01-01 - 2032-03-10

Phase III

Active
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes)

  • Condition/Disease

    Metabolic Dysfunction-Associated Steatotic Liver Disease

  • Test Drug

    Retatrutide (LY3437943) Tirzepatide (LY3298176)

Participate Sites
15Sites

Not yet recruiting8Sites

Recruiting7Sites

2023-09-01 - 2027-04-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting5Sites

2023-10-31 - 2027-08-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting7Sites

2025-01-01 - 2029-12-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2026-01-01 - 2029-08-31

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting4Sites

2018-11-30 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting8Sites

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB